A Phase 1b expansion study of ARGX-110 in patients with different subtypes of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Trial Profile

A Phase 1b expansion study of ARGX-110 in patients with different subtypes of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2017 New trial record
    • 14 Jun 2017 Results (n=16) published in an argenx Media Release
    • 14 Jun 2017 Updated data from trial presented at the International Conference of Malignant Lymphoma (ICML) 2017, as reported in an argenx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top